Semaglutide vs Tirzepatide: What’s the Difference?

Last Updated: September 21, 2026

Semaglutide and tirzepatide are both incretin-based prescription medicines, but they are different molecules with different receptor targets.

Semaglutide activates the GLP-1 receptor, while tirzepatide activates both GIP and GLP-1 receptors. Understanding this distinction makes it easier to compare how the two medicines work, how they have been studied, and how their approved uses differ.

Approval status and indications vary by product, formulation and country.

Semaglutide vs Tirzepatide at a Glance

The key point is that semaglutide and tirzepatide should not be considered interchangeable simply because both affect incretin pathways or are used in weight-management settings.

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist that selectively activates the glucagon-like peptide-1 receptor.

GLP-1 is involved in appetite and calorie-intake regulation. Semaglutide also stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner and can delay gastric emptying.

These combined effects help explain its role in glucose regulation and weight management.

Semaglutide is the active ingredient in several prescription products, and the approved indication depends on the specific product and formulation.

For example, in the United States, Wegovy is approved for long-term weight reduction in defined populations. Certain Wegovy indications also include cardiovascular risk reduction, while the injectable formulation has an accelerated approval indication for certain adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced fibrosis. Wegovy is now available in both injectable and oral formulations in the United States, with formulation-specific indications.

Ozempic, another semaglutide product, is approved for adults with type 2 diabetes and has additional cardiovascular and kidney-related indications in specified patient populations.

What Is Tirzepatide?

Tirzepatide is a dual GIP and GLP-1 receptor agonist.

Unlike semaglutide, which selectively activates GLP-1 receptors, tirzepatide activates receptors for both glucose-dependent insulinotropic polypeptide, or GIP, and GLP-1.

GLP-1 participates in appetite and calorie-intake regulation, while nonclinical evidence suggests that GIP receptor activity may also contribute to regulation of food intake.

In the United States, tirzepatide is marketed under different brand names depending on the indication.

Zepbound is approved for long-term weight reduction in certain adults with obesity or overweight and for treatment of moderate-to-severe obstructive sleep apnea in adults with obesity.

Mounjaro is approved for glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes. As of the August 2026 U.S. label update, Mounjaro is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for these events.

The Main Difference: One Receptor vs Two

The fundamental pharmacologic difference between semaglutide and tirzepatide is receptor targeting.

Semaglutide:

GLP-1 → GLP-1 receptor

Tirzepatide:

GIP + GLP-1 → GIP receptor + GLP-1 receptor

Both affect pathways involved in appetite, food intake and glucose regulation, but tirzepatide's additional GIP receptor activity means its pharmacology is not identical to that of semaglutide.

That difference should not automatically be interpreted as meaning that one medication is appropriate for every patient or indication. Clinical decisions also depend on the approved indication, patient characteristics, contraindications, tolerability and treatment goals.

What Does Head-to-Head Clinical Evidence Show?

Semaglutide and tirzepatide have been directly compared in randomized clinical trials, including studies of obesity and type 2 diabetes.

SURMOUNT-5: Adults With Obesity Without Diabetes

The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, directly compared tirzepatide with semaglutide in 751 adults with obesity without type 2 diabetes.

Participants received the maximum tolerated dose of either:

• tirzepatide 10 mg or 15 mg once weekly, or
• semaglutide 1.7 mg or 2.4 mg once weekly

for 72 weeks.

The mean change in body weight was:

• Tirzepatide: −20.2%
• Semaglutide: −13.7%

Mean waist circumference decreased by:

• Tirzepatide: −18.4 cm
• Semaglutide: −13.0 cm

The trial reported a greater average reduction in body weight and waist circumference with tirzepatide under these specific study conditions.

However, the findings should be interpreted within the study design. SURMOUNT-5 included adults with obesity without type 2 diabetes, used maximum tolerated doses, lasted 72 weeks, was open-label, and was funded by Eli Lilly.

Its results should therefore not be interpreted as evidence that one medicine is universally preferable for every patient.

What About People With Type 2 Diabetes?

Another direct comparison was conducted in the SURPASS-2 trial.

Adults with type 2 diabetes receiving metformin were treated for 40 weeks with tirzepatide 5 mg, 10 mg or 15 mg, or semaglutide 1 mg.

Average HbA1c reductions were:

• Tirzepatide 5 mg: −2.01 percentage points
• Tirzepatide 10 mg: −2.24 percentage points
• Tirzepatide 15 mg: −2.30 percentage points
• Semaglutide 1 mg: −1.86 percentage points

Weight reductions also differed across treatment groups.

Importantly, the semaglutide comparator in this trial was 1 mg, so these results should not be directly extrapolated to higher semaglutide doses used for obesity treatment.

Do They Have Similar Side Effects?

Both semaglutide and tirzepatide commonly cause gastrointestinal adverse effects, particularly during dose escalation.

Frequently reported effects include:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal discomfort or pain
• Dyspepsia

Both medicines also carry important warnings and precautions related to conditions including pancreatitis, gallbladder disease, severe gastrointestinal reactions and kidney injury associated with volume depletion. Individual product labels contain additional safety information.

U.S. prescribing information for both products also contains a boxed warning concerning thyroid C-cell tumors observed in rodents. It is unknown whether these medicines cause medullary thyroid carcinoma in humans, and they are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Individual risks and contraindications must be assessed by a qualified healthcare professional.

Can Semaglutide and Tirzepatide Be Used Together?

These medicines should not be combined unless specifically supported by an approved product label and medical guidance.

Current U.S. prescribing information for Wegovy advises against concomitant use with other semaglutide-containing products or other GLP-1 receptor agonists. Zepbound similarly advises against coadministration with other tirzepatide-containing products or GLP-1 receptor agonists.

They should therefore not be viewed as complementary weight-management medicines to be routinely taken together.

Semaglutide vs Tirzepatide: Why the Molecule Matters

Brand names can sometimes make the comparison confusing.

At the molecule level, the distinction is simpler:

Semaglutide = GLP-1 receptor agonist

Tirzepatide = GIP + GLP-1 receptor agonist

That receptor difference influences their pharmacology and clinical development, but treatment decisions cannot be based on receptor count alone.

Approved indication, patient age, metabolic disease, cardiovascular or renal disease, other medical conditions, potential adverse effects and local regulatory approval all matter when selecting therapy.

Frequently Asked Questions

Is tirzepatide the same as semaglutide?

No. They are different active pharmaceutical ingredients.

Semaglutide selectively activates the GLP-1 receptor, whereas tirzepatide activates both GIP and GLP-1 receptors. Their approved indications and available formulations also differ.

Is tirzepatide a GLP-1 medication?

Tirzepatide acts on the GLP-1 receptor, but it is more precisely described as a dual GIP and GLP-1 receptor agonist.

Semaglutide, in comparison, is a GLP-1 receptor agonist without GIP receptor agonism.

Which produced more weight loss in a direct clinical trial?

In the 72-week SURMOUNT-5 trial involving adults with obesity without type 2 diabetes, the mean weight change was −20.2% with tirzepatide and −13.7% with semaglutide.

These results apply to the specific study population, doses and treatment duration and do not determine which medicine is appropriate for an individual patient.

Are semaglutide and tirzepatide both approved for weight management?

Specific products containing both molecules have weight-management indications in the United States.

However, approval status differs by brand, formulation, age group, indication and country. The local regulatory label should always be checked rather than assuming approval based solely on the active ingredient.

Are semaglutide and tirzepatide both injections?

Not exclusively.

Tirzepatide products currently referenced in U.S. prescribing information are injectable. Semaglutide is available in injectable formulations, and certain semaglutide products are also available as oral tablets. Current U.S. Wegovy labeling includes both injection and oral tablet formulations.

Availability and approval vary internationally.

What are the common side effects?

Gastrointestinal adverse effects are among the most commonly reported effects for both medicines.

These include nausea, diarrhea, vomiting, constipation and abdominal symptoms. Serious adverse reactions can also occur, so treatment requires appropriate medical assessment and monitoring.

Can I switch from semaglutide to tirzepatide?

Switching between prescription medicines requires individualized clinical assessment.

Dose escalation schedules, previous tolerability, other medications, medical history and the approved indication should be reviewed by the prescribing healthcare professional rather than using a self-directed dose conversion.

Which one should I take?

There is no single answer that applies to every patient.

Semaglutide and tirzepatide have different receptor profiles, product-specific indications, clinical evidence and safety considerations. A licensed healthcare professional should determine whether either medicine is appropriate based on the individual's medical history, treatment goals and local prescribing information.

Conclusion

Semaglutide and tirzepatide belong to related incretin-based treatment categories but are pharmacologically distinct medicines.

Semaglutide works through GLP-1 receptor activation, while tirzepatide activates both GIP and GLP-1 receptors.

Head-to-head studies have identified differences in clinical outcomes under specific trial conditions, but those results should be interpreted according to the population, dose, indication and duration studied rather than generalized to every patient.

Understanding the active molecule provides a clearer foundation for comparing these medicines than relying on brand names alone.

References

1. U.S. National Library of Medicine, DailyMed. Wegovy (semaglutide) Prescribing Information, updated June 2026.
2. U.S. National Library of Medicine, DailyMed. Ozempic (semaglutide) Prescribing Information, 2026.
3. U.S. National Library of Medicine, DailyMed. Zepbound (tirzepatide) Prescribing Information, 2026.
4. U.S. National Library of Medicine, DailyMed. Mounjaro (tirzepatide) Prescribing Information, updated August 2026.
5. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. 2025;393:26–36. DOI: 10.1056/NEJMoa2416394.
6. Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.

Medical Disclaimer

This content is for general educational purposes only and is not medical advice. Semaglutide and tirzepatide are prescription-only medicines and must be prescribed by a licensed healthcare professional. Approval status and availability vary by country. Always consult local regulatory guidance and a qualified physician before making treatment decisions.

Regulatory status reflects information available at publication and may change; verify current information with the relevant authority, including the FDA, EMA, MHRA or MFDS.